These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 8807049)

  • 21. In vitro activity of the new quinolone lomefloxacin against Mycobacterium tuberculosis.
    Piersimoni C; Morbiducci V; Bornigia S; De Sio G; Scalise G
    Am Rev Respir Dis; 1992 Dec; 146(6):1445-7. PubMed ID: 1333738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro synergistic activity of clofazimine and other antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis isolates.
    Zhang Z; Li T; Qu G; Pang Y; Zhao Y
    Int J Antimicrob Agents; 2015 Jan; 45(1):71-5. PubMed ID: 25459737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data.
    Angeby KA; Jureen P; Giske CG; Chryssanthou E; Sturegård E; Nordvall M; Johansson AG; Werngren J; Kahlmeter G; Hoffner SE; Schön T
    J Antimicrob Chemother; 2010 May; 65(5):946-52. PubMed ID: 20332195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies.
    Bajaksouzian S; Visalli MA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1997 May; 41(5):1073-6. PubMed ID: 9145872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis.
    De Logu A; Onnis V; Saddi B; Congiu C; Schivo ML; Cocco MT
    J Antimicrob Chemother; 2002 Feb; 49(2):275-82. PubMed ID: 11815568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [MICs and MBCs of levofloxacin, clarithromycin, and KRM-1648 for Mycobacterium tuberculosis and M. avium complex residing in MONO-MAC-6 human macrophage-like cell and A-549 human type II alveolar epithelial cell lines].
    Sato K; Ogasawara K; Akaki T; Tomioka H
    Kekkaku; 1999 Jul; 74(7):571-7. PubMed ID: 10481412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis.
    Rodríguez JC; Ruiz M; Climent A; Royo G
    Int J Antimicrob Agents; 2001 Mar; 17(3):229-31. PubMed ID: 11282270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antituberculosis agents. VI. Activity of a new ciprofloxacin derivative against Mycobacterium avium and some drug-resistant strains of Mycobacterium tuberculosis.
    Foroumadi A; Soltani F; Moshafi MH
    Boll Chim Farm; 2002; 141(5):394-6. PubMed ID: 12481384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs.
    Ruiz-Serrano MJ; Alcalá L; Martínez L; Díaz M; Marín M; González-Abad MJ; Bouza E
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2567-8. PubMed ID: 10952620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In-vitro susceptibility of Streptococcus pneumoniae to the d- and l-isomers of ofloxacin: interpretive criteria and quality control limits.
    Barry AL; Fuchs PC; Allen SD; Brown SD; Jorgensen JH; Tenover FC
    J Antimicrob Chemother; 1996 Feb; 37(2):365-9. PubMed ID: 8707749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Evaluation of levofloxacin antitubercular activity in vitro and in lung tissue culture].
    Sokolova GB; Kunichan AD; Litovchenko KV; Tsybanev AA
    Antibiot Khimioter; 2002; 47(12):15-9. PubMed ID: 12728630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study of the in vitro susceptibility of M. tuberculosis to ofloxacin in Spain. Spanish Study Group of M. tuberculosis resistance.
    Casal M; Ruiz P; Herreras A
    Int J Tuberc Lung Dis; 2000 Jun; 4(6):588-91. PubMed ID: 10864193
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Tudó G; Lopez-Gavin A; Portell-Buj E; Freixes J; Vila J; Roman A; Monté MR; Gonzalez-Martin J
    Microb Drug Resist; 2020 Sep; 26(9):1019-1022. PubMed ID: 32159449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity against Mycobacterium tuberculosis of levofloxacin, moxifloxacin and UB-8902 in combination with clofazimine and pretomanid.
    López-Gavín A; Tudó G; Vergara A; Hurtado JC; Gonzalez-Martín J
    Int J Antimicrob Agents; 2015 Nov; 46(5):582-5. PubMed ID: 26421981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A whole blood bactericidal assay for tuberculosis.
    Wallis RS; Palaci M; Vinhas S; Hise AG; Ribeiro FC; Landen K; Cheon SH; Song HY; Phillips M; Dietze R; Ellner JJ
    J Infect Dis; 2001 Apr; 183(8):1300-3. PubMed ID: 11262217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin.
    Nosova EY; Bukatina AA; Isaeva YD; Makarova MV; Galkina KY; Moroz AM
    J Med Microbiol; 2013 Jan; 62(Pt 1):108-113. PubMed ID: 23019190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of levofloxacine on cell elements of the lung tissue and on the growth of drug resistant Mycobacteria tuberculosis].
    Sokolova GB; Semenova OV; Bogadel'nikova IV; Kunichan AD
    Antibiot Khimioter; 2002; 47(6):12-7. PubMed ID: 12422642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Susceptibility to levofloxacin of Myocobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical Research on AIDS 019 and the AIDS Clinical Trials Group 222 Protocol Team.
    Perlman DC; El Sadr WM; Heifets LB; Nelson ET; Matts JP; Chirgwin K; Salomon N; Telzak EE; Klein O; Kreiswirth BN; Musser JM; Hafner R
    AIDS; 1997 Oct; 11(12):1473-8. PubMed ID: 9342069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355).
    Saito H; Sato K; Tomioka H; Dekio S
    Tuber Lung Dis; 1995 Oct; 76(5):377-80. PubMed ID: 7495996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin.
    Rastogi N; Goh KS
    Antimicrob Agents Chemother; 1991 Sep; 35(9):1933-6. PubMed ID: 1952872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.